Saturday, November 22, 2025 7:13:02 AM
I don't, but the UK isn't doing well economically right now and see below:
Okay 50k P.S. is app 65K $
AI overview:
NICE does not pay for cancer treatments directly; instead, it assesses the cost-effectiveness of new treatments for the NHS
. The typical threshold NICE uses is £20,000 to £30,000 per quality-adjusted life year (QALY), but for cancer drugs, this is often higher. Since 2019, the general threshold has been effectively £50,000 per QALY for end-of-life cancer drugs that extend life by at least three months. The UK government also provides additional funding for certain cancer drugs that fall outside these thresholds through the Cancer Drugs Fund.
NICE's cost-effectiveness thresholds
General threshold: £20,000 to £30,000 per QALY for most treatments.
Cancer treatments: The threshold for cancer drugs is often higher, with a figure of £50,000 per QALY being used for medicines that extend life by at least three months.
Severity modifier: A newer system, introduced in 2022, allows for a higher threshold of up to £50,000 per QALY for highly severe conditions
Okay 50k P.S. is app 65K $
AI overview:
NICE does not pay for cancer treatments directly; instead, it assesses the cost-effectiveness of new treatments for the NHS
. The typical threshold NICE uses is £20,000 to £30,000 per quality-adjusted life year (QALY), but for cancer drugs, this is often higher. Since 2019, the general threshold has been effectively £50,000 per QALY for end-of-life cancer drugs that extend life by at least three months. The UK government also provides additional funding for certain cancer drugs that fall outside these thresholds through the Cancer Drugs Fund.
NICE's cost-effectiveness thresholds
General threshold: £20,000 to £30,000 per QALY for most treatments.
Cancer treatments: The threshold for cancer drugs is often higher, with a figure of £50,000 per QALY being used for medicines that extend life by at least three months.
Severity modifier: A newer system, introduced in 2022, allows for a higher threshold of up to £50,000 per QALY for highly severe conditions
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
